Foto de Damià Tormo Carulla Logotipo FPdGi Business Award

Scientist, entrepreneur, investor and partner at Columbus Venture Partners

Logotipo FPdGi Business Award

FPdGi Business Award 2017

Damià Tormo Carulla

Valencia, 1981

“In addition to putting on a lab coat, doing a PhD and conducting research, there are other paths and career opportunities. Who wouldn’t be motivated by a project which could provide solutions for cancer patients?”

Damià Tormo Carulla

WHY IT HAS BEEN AWARDED

«For combining a brilliant scientific career with being an entrepreneur and investor capable of connecting the world of research with successful entrepreneurial initiatives in Spain».

HISTORY

During his doctorate (in Germany, the USA and Spain), Damià worked on a project for a cancer treatment that worked very well. This discovery was widely recognised, but it was not reaching patients. So, he decided to give up his scientific career and seek funding to create a company that would make this treatment available to sick people. He did it.

He is the founder and managing partner of the Columbus Venture Partners fund and founder and board member of different biotechnology companies.

Damià is also chairman and founder of the Columbus Foundation, which facilitates access to the most advanced and effective therapies for children with cancer or rare diseases in order to improve their life expectancy and quality of life.

Watch video

“Many tasks seem easy under normal conditions, but when your child is sick, everything takes on a very different perspective. Thank you very much Columbus Foundation”

Mother of a sick child

EDUCATION AND AWARDS

Damià graduated in Biology from the University of Valencia and holds a doctorate in Immunology and Molecular Genetics from Rheinische Friedrich-Wilhelms-Universität Bonn (Germany). He also has an international master’s in Biotechnology Management (MBM) from IE Business School and has spent time as a student and researcher at institutions such as the University of Cambridge (UK), Michigan University (USA) and the Spanish National Cancer Research Centre (CNIO).